Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia

Upfront Of $28m

 
• By John Davis
  
Parkinson's disease
• Source: Alamy

More from Neurological

More from Therapy Areas